000			02144cam a2200349 a 4500
003			EG-GiCUC
005			20250223032334.0
008			190727s2019 ua d f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.10.M.Sc.2019.Re.P
100	0		_aReham Waheed Mahmoud Hammad
245	1	2	_aA pharmaceutical study on mosapride for intranasal administration / _cReham Waheed Mahmoud Hammad ; Supervised Nevine Shawky Abdelmalak , Randa Latif Aziz , Rania Abdelbaset Sanad
246	1	5	_aدراسة صيدلية علي عقار الموزابريد لاستخدامة عن طريق الانف
260			_aCairo : _bReham Waheed Mahmoud Hammad , _c2019
300			_a229 P. : _bcharts ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Industrial Pharmacy
520			_aMosapride citrate (MOS) is a potent gastroprokinetic agent, used in the treatment of various gastrointestinal disorders caused by reduced gastrointestinal motility including gastroesophageal reflux disease (GERD). MOS would neither result in cardiac nor nervous adverse reactions due to selective stimulation of serotonin 5-HT4 receptors, without any considerable affinity for dopamine D2, 5-HT1, 5-HT2, or adrenergic receptors. Presently, available tablet dosage formulation of MOS is incapable to achieve the required clinical efficacy. Its short half-life (t1/2), intensive first-pass metabolism, poor solubility, and poor wettability lower its oral bioavailability to be 8-14%.This very low oral bioavailability restricts its use. So, the aim of this study was to improve the bioavailability MOS through intranasal administration
530			_aIssued also as CD
653		4	_aMosapride citrate
653		4	_aNasal
653		4	_aXyloglucan
700	0		_aNevine Shawky Abdelmalak , _eSupervisor
700	0		_aRanda Latif Aziz , _eSupervisor
700	0		_aRania Abdelbaset Sanad , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aAsmaa _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c73081 _d73081